

Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy

Information for the public

Published: 5 October 2022

www.nice.org.uk

Azacitidine (Onureg) tablets are available on the NHS. It is a possible maintenance treatment for acute myeloid leukaemia in adults who:

- are in complete remission (even if the blood cell count is not back to normal), after induction therapy with or without consolidation treatment, and
- cannot have or do not want a stem cell transplant.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Care](#), 08088 010 444
- [Blood Cancer UK](#), 0808 169 5155
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4754-6